BioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 108,000 Shares

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Mark A. Sirgo sold 108,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $2.57, for a total value of $277,560.00. Following the transaction, the director now owns 1,759,262 shares in the company, valued at approximately $4,521,303.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

BioDelivery Sciences International, Inc. (NASDAQ BDSI) traded up $0.10 during trading hours on Monday, reaching $2.30. The company had a trading volume of 538,385 shares, compared to its average volume of 567,561. The stock has a market capitalization of $128.53, a price-to-earnings ratio of 25.56 and a beta of 0.50. BioDelivery Sciences International, Inc. has a 52-week low of $1.55 and a 52-week high of $3.60. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.07 and a current ratio of 1.28.

A number of large investors have recently added to or reduced their stakes in BDSI. Stonepine Capital Management LLC lifted its holdings in BioDelivery Sciences International by 11.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 3,867,400 shares of the specialty pharmaceutical company’s stock worth $11,409,000 after buying an additional 389,727 shares during the last quarter. Royce & Associates LP lifted its holdings in BioDelivery Sciences International by 43.0% during the 4th quarter. Royce & Associates LP now owns 1,848,600 shares of the specialty pharmaceutical company’s stock worth $5,453,000 after buying an additional 555,800 shares during the last quarter. EAM Investors LLC lifted its holdings in BioDelivery Sciences International by 62.1% during the 3rd quarter. EAM Investors LLC now owns 780,635 shares of the specialty pharmaceutical company’s stock worth $2,303,000 after buying an additional 299,163 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in BioDelivery Sciences International by 10.1% during the 2nd quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock worth $1,369,000 after buying an additional 44,700 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in BioDelivery Sciences International by 0.9% during the 2nd quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock worth $394,000 after buying an additional 1,203 shares during the last quarter. Hedge funds and other institutional investors own 44.16% of the company’s stock.

Several equities analysts have recently weighed in on the company. Piper Jaffray Companies set a $4.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Sunday, October 22nd. HC Wainwright set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, November 27th. Seaport Global Securities began coverage on BioDelivery Sciences International in a report on Friday, January 26th. They issued a “buy” rating and a $5.00 price target for the company. Finally, Roth Capital set a $5.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Monday, November 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. BioDelivery Sciences International has a consensus rating of “Buy” and an average target price of $4.38.

COPYRIGHT VIOLATION WARNING: “BioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 108,000 Shares” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/12/mark-a-sirgo-sells-108000-shares-of-biodelivery-sciences-international-inc-bdsi-stock.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply